PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
30.46%
Growth of 30.46% versus flat Healthcare revenue. Walter Schloss would verify growth quality.
9.53%
Cost growth of 9.53% versus flat Healthcare costs. Walter Schloss would verify cost control.
41.93%
Growth of 41.93% versus flat Healthcare gross profit. Walter Schloss would verify quality.
8.79%
Margin change of 8.79% versus flat Healthcare margins. Walter Schloss would verify quality.
42.65%
R&D change of 42.65% versus flat Healthcare spending. Walter Schloss would verify adequacy.
17.56%
G&A change of 17.56% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
-7.29%
Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
173.36%
Other expenses change of 173.36% versus flat Healthcare costs. Walter Schloss would verify efficiency.
8.78%
Operating expenses change of 8.78% versus flat Healthcare costs. Walter Schloss would verify control.
8.99%
Total costs change of 8.99% versus flat Healthcare costs. Walter Schloss would verify control.
129.01%
Interest expense change of 129.01% versus flat Healthcare costs. Walter Schloss would verify control.
51.17%
D&A growth exceeding 1.5x Healthcare median of 0.74%. Jim Chanos would check for overinvestment.
147.59%
EBITDA growth exceeding 1.5x Healthcare median of 0.88%. Joel Greenblatt would investigate advantages.
136.32%
Margin change of 136.32% versus flat Healthcare. Walter Schloss would verify quality.
82.60%
Operating income growth exceeding 1.5x Healthcare median of 2.31%. Joel Greenblatt would investigate advantages.
86.66%
Margin change of 86.66% versus flat Healthcare. Walter Schloss would verify quality.
163.77%
Other expenses change of 163.77% versus flat Healthcare. Walter Schloss would verify control.
100.85%
Pre-tax income growth exceeding 1.5x Healthcare median of 0.72%. Joel Greenblatt would investigate advantages.
100.65%
Margin change of 100.65% versus flat Healthcare. Walter Schloss would verify quality.
-96.84%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
100.85%
Net income growth exceeding 1.5x Healthcare median of 2.73%. Joel Greenblatt would investigate advantages.
100.65%
Margin change of 100.65% versus flat Healthcare. Walter Schloss would verify quality.
101.37%
EPS growth exceeding 1.5x Healthcare median of 6.03%. Joel Greenblatt would investigate advantages.
100.00%
Diluted EPS growth exceeding 1.5x Healthcare median of 5.56%. Joel Greenblatt would investigate advantages.
20.86%
Share count reduction below 50% of Healthcare median of 0.09%. Jim Chanos would check for issues.
61.58%
Diluted share reduction below 50% of Healthcare median of 0.12%. Jim Chanos would check for issues.